Castle Biosciences Inc

Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, Decision Dx DiffDx-Melanoma, DecisonDx-CMSeq, DecisionDx-SCC, DecsionDx-UMSeq, and DecisonDX-PRAME. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Castle Biosciences posts robust Q4 earnings, eyes growth opportunities ahead

Castle Biosciences reported strong financial performance in Q4 and full-year 2022, driven by revenue growth and test volume increase.
The company's focus on expanding commercial teams, R&D initiatives, and new laboratory openings positions it for future growth.
Challenges lie in convincing commercial payers and maintaining gross margin, requiring strategic actions and evidence-based outcomes.
Opportunities exist in demonstrating patient outcomes, NCCN guideline inclusion, and leveraging cash reserves for growth.

Castle Biosciences reports robust Q1 performance and navigates growth challenges

Castle Biosciences delivered a strong Q1 2023 with notable revenue growth and volume increases, supported by a solid financial position.
The company's focus on dermatology, gastroenterology, and mental health segments, along with positive clinical study results, underpin its market strength.
While facing challenges in sales execution and territory management, Castle Biosciences is strategically positioned to capitalize on growth opportunities in its key product lines.

Castle Biosciences reports robust Q2 growth and navigates coverage challenges

Castle Biosciences delivered strong financial performance in Q2 2023, with revenue and test volume growth surpassing expectations.
Despite challenges in coverage and operational constraints, the company's strategic focus on test value and market expansion presents promising growth prospects.
With a solid financial position, ongoing efforts to address challenges, and capitalize on opportunities, Castle Biosciences is poised for continued success in the precision medicine market.

Castle Biosciences reports stellar Q3 results and eyes market expansion

Castle Biosciences delivered exceptional financial results, raised revenue guidance, and showcased strong growth across its test portfolio. The company's focus on innovation, clinical impact, and market recognition positions it well for future success. While challenges in managing growth and competition exist, Castle Biosciences has opportunities to capitalize on its strengths and expand its market presence.

Castle Biosciences reports stellar 2023 performance and eyes new markets

Castle Biosciences delivered strong financial performance in Q4 and full year 2023, driven by robust revenue growth and impressive test volume results across key tests.
The company showcased clinical efficacy, innovation, and financial discipline, while navigating challenges such as cost pressures and reimbursement uncertainties.
Strategic initiatives like expanding test portfolios, managing costs effectively, and exploring new growth avenues position Castle Biosciences for continued success and market leadership.
With a focus on maintaining profitability, investing in growth, and leveraging opportunities, Castle Biosciences is poised for sustained growth and value creation in the future.

Castle Biosciences excels in Q1 2024, eyes strategic growth opportunities

Castle Biosciences delivered exceptional financial and operational results in Q1 2024, showcasing strong revenue growth, improved margins, and product advancements. While facing some challenges with test volumes and Medicare coverage, the company's solid performance and market position present promising opportunities for future growth.

Castle Biosciences excels in Q2, raises guidance amid test volume surge

Castle Biosciences delivered outstanding financial results in Q2 2024, showcasing strong revenue growth, improved margins, and a significant net income turnaround.
The company's focus on innovation and clinical value in its tests positions it well for sustained growth and market leadership in precision diagnostics.
While facing challenges in maintaining growth momentum and operational efficiency, Castle Biosciences has opportunities to expand its market presence and drive international expansion.
Overall, Castle Biosciences' Q2 performance reflects a resilient and promising trajectory, underpinned by strategic strengths and a commitment to advancing patient care.

Castle Biosciences excels in Q3, poised for sustained growth

Castle Biosciences' Q3 performance reflects strong revenue growth, financial stability, and a positive outlook for future expansion.
The company's focus on product innovation, market penetration, and financial discipline positions it well for continued success.
While challenges exist in maintaining growth and profitability, Castle Biosciences has ample opportunities for further market expansion and value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle will ring the Nasdaq closing bell on Wednesday, Sept. 27, 2023, to raise awareness of melanoma in honor of patients impacted by the disease.

Castle Biosciences, Leading Skin Cancer Expert, Darrell Rigel, M.D., M.S., and IMPACT Melanoma Board Member to Ring Nasdaq Closing Bell on Sept.

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--National award recognizes Castle's strong culture and employee engagement.

Castle Biosciences Ranked Third Among 2023 Top Workplaces in the Healthcare Industry

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #AI--Study shows TissueCypher outperformed pathology review in predicting progression to high-grade dysplasia or esophageal cancer in Barrett's patients.

TissueCypher® Barrett's Esophagus Test Outperformed Standard of Care in Risk-Stratifying Patients with Barrett's Esophagus

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle Biosciences has received its Clinical Laboratory Permit from the New York State Department of Health for its laboratory in Pittsburgh.

Castle Biosciences Announces Receipt of New York Laboratory Permit for Pittsburgh Laboratory

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle announced data from a study of its IDgenetix® test that was recently shared at Psych Congress 2023.

Integrating Drug-Drug Interactions and Lifestyle Factors with Drug-Gene Interactions Provided by Castle Biosciences' IDgenetix® Test Significantly Impacted the Number of Drug Recommendations for Patients with Moderate to Severe Depression

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #BarretsEsophagus--Castle will share new data on its TissueCypher® test during the Presidential Plenary Session of the 19th ISDE World Congress for Esophageal Diseases.

TissueCypher® Provides Clinically-Impactful Risk Stratification in Patients with Barrett's Esophagus

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle will share a poster detailing new data regarding the Company's IDgenetix® test at the upcoming Psych Congress 2023 conference.

Castle Biosciences to Highlight Clinical Value of IDgenetix® Test at Psych Congress 2023

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #BarretsEsophagus--Castle announced a new study showing how TissueCypher® test results can significantly improve management decisions for Barrett's esophagus patients.

New Publication Highlights the Ability of the TissueCypher® Barrett's Esophagus Test to Improve and Standardize the Clinical Management of Low-Grade Dysplasia in Patients with Barrett's Esophagus

Castle reported stronger Q2 revenue growth and a lower net loss than analysts anticipated. The company also raised its full-year revenue outlook.

Why Castle Biosciences Stock Is Jumping Today

Castle Biosciences, Inc. (NASDAQ:CSTL ) Q2 2023 Earnings Conference Call August 2, 2023 4:30 PM ET Company Participants Camilla Zuckero - Vice President, Investor Relations & Corporate Affairs Derek Maetzold - Founder, President & Chief Executive Officer Frank Stokes - Chief Financial Officer Conference Call Participants Carl Nixon - Canacord Sung Ji Nam - Scotiabank Thomas Flaten - Lake Street Capital Markets Puneet Souda - SVB Mason Carrick - Stevens Catherine Schulte - Baird Mark Massaro - BTIG Operator Good afternoon, and welcome to Castle Biosciences Second Quarter 2023 Conference Call. As a reminder, today's call is being recorded.

Castle Biosciences, Inc. (CSTL) Q2 2023 Earnings Call Transcript

While the top- and bottom-line numbers for Castle Biosciences, Inc. (CSTL) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Here's What Key Metrics Tell Us About Castle Biosciences, Inc. (CSTL) Q2 Earnings

Castle Biosciences, Inc. (CSTL) came out with a quarterly loss of $0.70 per share versus the Zacks Consensus Estimate of a loss of $1.01. This compares to loss of $0.06 per share a year ago.

Castle Biosciences, Inc. (CSTL) Reports Q2 Loss, Tops Revenue Estimates

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #earnings--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the second quarter and six months ended June 30, 2023. “Castle delivered an outstanding second quarter, with strength across our entire test portfolio,” said Derek Maetzold, president and chief executive officer of Castle Biosciences. “Building on our first quarter momentum and driven by consistent ex.

Castle Biosciences Reports Second Quarter 2023 Results

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle is scheduled to present a company overview at the Canaccord Genuity 43rd Annual Growth Conference on Aug. 9 at 12:00 p.m. Eastern time.

Castle Biosciences to Present at the Canaccord Genuity 43rd Annual Growth Conference

Castle Biosciences, Inc. (CSTL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Castle Biosciences, Inc. (CSTL) Q2 Earnings Expected to Decline

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle will release its financial results for the second quarter and six months ended June 30, 2023, after the close of market on Aug. 2, 2023.

Castle Biosciences to Release Second Quarter 2023 Financial Results and Host Conference Call on Wednesday, Aug. 2

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle will host its second company-wide Castle Cares Charity Walk on Tuesday, July 18, 2023, in Orlando, Florida, and virtually.

Castle Biosciences to Host Second Annual Castle Cares Charity Walk

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle has earned a second consecutive Arizona Top Workplace award from AZ Central, the digital home of The Arizona Republic newspaper.

Castle Biosciences Honored as an Arizona Top Workplace for the Second Consecutive Year

LOS ANGELES, CA / ACCESSWIRE / July 17, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Castle Biosciences, Inc. ("Castle Biosciences" or "the Company") (NASDAQ:CSTL) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Castle Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm

Castle's CEO and board chairman each unloaded significant amounts of company stock. The company focuses on medical diagnostic tests, primarily to inform cancer treatment choices.

Why Shares of Castle Biosciences Fell This Week

Castle Biosciences, Inc shares surged 55% to $20.64 on Friday after Novitas, a regional Medicare administrative contractor, reversed its draft policy that would have denied coverage of Castle's DecisionDx cancer tests for squamous cell carcinoma (SCC) and melanoma. Novitas stated that its original local coverage determination (LCD) was scheduled to go into effect on July 17, 2023, and now plans to create a new draft LCD for Castle's DecisionDx tests.

Castle Biosciences stock soars on Medicare reversal; data presentation

Novitas is withdrawing a draft policy that would have denied coverage for Castle's cancer tests. It must still wait on a new draft policy from the regional Medicare administrative contractor.

Why Castle Biosciences Stock Is Crushing It Today

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle will present new data on DecisionDx®-SCC and DecisionDx®-Melanoma at AHNS' 11th International Conference on Head and Neck Cancer.

Castle Biosciences to Present New DecisionDx®-SCC and DecisionDx®-Melanoma Data at the American Head & Neck Society's (AHNS) 11th International Conference on Head and Neck Cancer

LOS ANGELES, CA / ACCESSWIRE / July 7, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Castle Biosciences, Inc. ("Castle Biosciences" or "the Company") (NASDAQ:CSTL) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Castle Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / July 3, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Castle Biosciences, Inc. ("Castle Biosciences" or "the Company") (NASDAQ:CSTL) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Castle Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm

News for Castle Biosciences Inc Stock (CSTL)